Groupe Hospitalier Pellegrin | ClinicalTrials HQ

9 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)	CNS demyelinating autoimmune disease, autoimmune disease, autoimmune disorder of the nervous system, demyelinating disease, immune system disorder, multiple sclerosis, nervous system disorder, relapsing-remitting multiple sclerosis	Active, not recruiting	Phase 3	2026-09-28		NCT04544436
A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis	CNS demyelinating autoimmune disease, Chronic Disease, Disease Attributes, Multiple Sclerosis, Primary Progressive, Pathologic Processes, Pathological Conditions, Signs and Symptoms, autoimmune disease, autoimmune disorder of the nervous system, chronic progressive multiple sclerosis, demyelinating disease, immune system disorder, multiple sclerosis, nervous system disorder	Active, not recruiting	Phase 3	2026-09-17		NCT04544449
COsegregation of VARiants in Panel of Genes	Disease Attributes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, disease susceptibility, inherited disease susceptibility	Recruiting	Not applicable	2026-09-01		NCT01689584
GENERATION HD2. A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen Compared With Placebo in Participants With Prodromal and Early Manifest Huntington's Disease	Cognition Disorders, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Dyskinesias, Huntington disease, basal ganglia disorder, brain disorder, central nervous system disorder, choreatic disease, cognitive disorder, dementia, hereditary disease, inherited neurodegenerative disorder, movement disorder, nervous system disorder, neurodegenerative disease, psychiatric disorder	Active, not recruiting	Phase 2	2026-08-10		NCT05686551
French Childhood Cancer Survivor Study	Childhood Solid Tumor	Recruiting	Not stated	2026-07-30		NCT01620372
A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis	CNS demyelinating autoimmune disease, autoimmune disease, autoimmune disorder of the nervous system, demyelinating disease, immune system disorder, multiple sclerosis, nervous system disorder	Active, not recruiting	Phase 3	2026-07-29		NCT05269004
A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis	CNS demyelinating autoimmune disease, Chronic Disease, Disease Attributes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, autoimmune disease, autoimmune disorder of the nervous system, chronic progressive multiple sclerosis, demyelinating disease, immune system disorder, multiple sclerosis, nervous system disorder	Active, not recruiting	Phase 3	2026-07-23		NCT03523858
An Extension Study to Assess Impact of Multiple Sclerosis (MS) on Physical Function and Provide Continued Ocrelizumab Treatment	CNS demyelinating autoimmune disease, autoimmune disease, autoimmune disorder of the nervous system, demyelinating disease, immune system disorder, multiple sclerosis, nervous system disorder	Recruiting	Phase 3	2026-02-18		NCT06675955
A Study to Assess the Efficacy, Safety, and Pharmacokinetics of FNP-223 to Slow Progression of Progressive Supranuclear Palsy (PSP)	Disease Attributes, Disease Progression, Neurologic Manifestations, Ocular Motility Disorders, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, basal ganglia disorder, brain disorder, central nervous system disorder, cranial nerve neuropathy, eye disorder, movement disorder, nervous system disorder, neurodegenerative disease, ophthalmoplegia, palsy, progressive supranuclear palsy, tauopathy	Active, not recruiting	Phase 2	2025-10-15		NCT06355531